Loading…
Precigen, Inc. is projected to rise to $8.01 by 2027, a +35% move from its current price of $5.94. PGEN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $5.73 | $5.94 | $6.16 | +0.07% |
| Aug 2 | $5.65 | $5.95 | $6.26 | +0.13% |
| Aug 3 | $5.59 | $5.95 | $6.33 | +0.20% |
| Aug 4 | $5.54 | $5.96 | $6.40 | +0.26% |
| Aug 5 | $5.50 | $5.96 | $6.46 | +0.33% |
| Aug 6 | $5.46 | $5.96 | $6.51 | +0.39% |
| Aug 7 | $5.43 | $5.97 | $6.56 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.43 | $5.97 | $6.56 | +0.46% |
| Week 2 | $5.24 | $5.99 | $6.86 | +0.92% |
| Week 3 | $5.11 | $6.02 | $7.10 | +1.38% |
| Week 4 | $5.00 | $6.05 | $7.31 | +1.84% |
| Week 5 | $4.91 | $6.08 | $7.52 | +2.31% |
| Week 6 | $4.84 | $6.10 | $7.70 | +2.77% |
| Week 7 | $4.77 | $6.13 | $7.88 | +3.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
The company is developing programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, it develops programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device.
The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen, Inc. (PGEN) is a healthcare company currently priced at $5.94 per share. Its market cap is $2.12B and it ranks 1869. The stock sits in the healthcare space with a market capitalization around $2.12B and a share price of $5.94.
The long-term outlook from the forecast suggests growing value across years, with 2026 showing an average price near the current level and rising averages through 2030, 2040, and 2050. Projected returns (ROI) grow substantially in later years, culminating in sizable upside by 2050.
A major floor 47.8% below — a decisive break under it would weaken the trend.
The nearest floor, 20.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 13.6% above — clearing it would confirm fresh momentum.
Key PGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.55 | Buy | $5.61 | Buy |
| MA 10 | $5.41 | Buy | $5.49 | Buy |
| MA 20 | $5.38 | Buy | $5.36 | Buy |
| MA 50 | $4.90 | Buy | $5.01 | Buy |
| MA 100 | $4.39 | Buy | $4.65 | Buy |
| MA 200 | $4.26 | Buy | $4.17 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.22 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 183.23 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 16.02 | Buy |
| Bollinger %B (20,2) | 1.07 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.25 | Buy |
| Ultimate (7,14,28) | 66.27 | Neutral |
| Momentum (10) | 0.99 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 5.65 | Buy |
| ADX (14) | 17.42 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture is bullish, with RSI14 at 70. The stock trades above the SMA50 of $4.90 and above the SMA200 of $4.26. This combination supports a constructive near-term bias.
Support is identified at $4.73 and resistance at $5.94, framing the near-term trading range. The 30-day range spans from $4.69 to $7.53, indicating potential for additional upside within a relatively tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.10 | $5.94 | $8.12 | 0% | Neutral | |
| $6.20 | $8.01 | $11.04 | +35% | Bullish | |
| $6.88 | $9.23 | $13.34 | +55% | Bullish | |
| $7.31 | $10.12 | $15.17 | +70% | Bullish | |
| $8.73 | $12.44 | $19.21 | +109% | Bullish | |
| $10.36 | $15.16 | $24.04 | +155% | Bullish | |
| $13.69 | $20.52 | $33.31 | +245% | Bullish | |
| $16.13 | $24.75 | $41.04 | +317% | Bullish | |
| $15.20 | $23.84 | $40.32 | +301% | Bullish | |
| $16.91 | $27.09 | $46.64 | +356% | Bullish | |
| $29.21 | $51.60 | $95.71 | +769% | Bullish | |
| $45.83 | $96.60 | $199.39 | +15.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.10 | $5.94 | $6.94 | +0.00% |
| August 2026 | $5.12 | $6.04 | $7.34 | +1.76% |
| September 2026 | $5.28 | $6.30 | $7.79 | +4.29% |
| October 2026 | $5.20 | $6.27 | $7.86 | -0.48% |
| November 2026 | $5.05 | $6.14 | $7.77 | -2.17% |
| December 2026 | $5.20 | $6.35 | $8.12 | +3.50% |
Click any year to see its month-by-month PGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Precigen, Inc.'s 2026 outlook centres on $5.94, within a $3.10 to $8.12 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, PGEN could reach as high as $11.04, with a base case around $8.01 and support toward $6.20 — roughly +35% from $5.94. Momentum favours further upside here.
Expect PGEN to range from $6.88 to $13.34 through 2028. The $9.23 average target implies a +55% move from current prices. That is up +15% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The PGEN price prediction for 2029 points to an average of $10.12 (low $7.31, high $15.17) — a potential gain of +70% on today's $5.94. Momentum favours further upside here.
In 2030, PGEN is projected to trade between $8.73 and $19.21, averaging $12.44 — a potential gain of +109% from today's $5.94. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Precigen, Inc.'s 2031 outlook centres on $15.16, within a $10.36 to $24.04 range. That is up +22% on the projected 2030 average. That marks a +155% change versus current levels. Momentum favours further upside here.
By 2032, PGEN could reach as high as $33.31, with a base case around $20.52 and support toward $13.69 — roughly +245% from $5.94. Buyers look set to stay in control over this stretch.
Expect PGEN to range from $16.13 to $41.04 through 2033. The $24.75 average target implies a +317% move from current prices. That is up +21% on the projected 2032 average. Momentum favours further upside here.
The PGEN price prediction for 2034 points to an average of $23.84 (low $15.20, high $40.32) — a potential gain of +301% on today's $5.94. Buyers look set to stay in control over this stretch.
In 2035, PGEN is projected to trade between $16.91 and $46.64, averaging $27.09 — a potential gain of +356% from today's $5.94. That is up +14% on the projected 2034 average. Momentum favours further upside here.
Precigen, Inc.'s 2040 outlook centres on $51.60, within a $29.21 to $95.71 range. That is up +90% on the projected 2035 average. That marks a +769% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, PGEN could reach as high as $199.39, with a base case around $96.60 and support toward $45.83 — roughly +15.3x from $5.94. Momentum favours further upside here.
Investing $1,000 in PGEN today (≈ 168.350168 PGEN) could be worth
$16,262.01
+$15,262.01 (+1526%) by 2050 · US Dollar
Based on the average projected PGEN price of $96.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PGENwould be worth at today's price.
$1,000 invested in PGEN on Jul 30, 2025 (≈ 578.034676 PGEN) would be worth
$3,433.53
+$2,433.53 (+243.4%) today · 3.43× · US Dollar
Based on a PGEN entry price of $1.73 vs. today's $5.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.54 | $1,072.2 | +7.2% |
| 1 month ago | $5.7 | $1,042.11 | +4.2% |
| 3 months ago | $4.08 | $1,455.88 | +45.6% |
| 6 months ago | $4.49 | $1,322.94 | +32.3% |
| 1 year ago | $1.73 | $3,433.53 | +243.4% |
| All time (5.0y) ago | $5.61 | $1,058.82 | +5.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PGEN forecast.
Our base-case forecast reaches $12.00 around 2030.
Implied market cap at $12.00: $4.28B
The multi-year forecast shows a bullish sentiment across the years, with 2026 offering a base near $5.94 on a min/avg/max basis of $3.10/$5.94/$8.12 and an ROI of 0. In 2027 the average price is forecast at $8.01 with a 34.8% ROI, followed by 2028 at $9.23 (55.5% ROI) and 2029 at $10.12 (70.4% ROI). The outlook improves markedly into the 2030s, with 2030 averaging $12.44 and a max of $19.21, yielding a 109.4% ROI and a bullish sentiment.
Looking further out, 2040 shows an average of $51.60 with a min of $29.21 and a max of $95.71, representing a 768.7% ROI and continued bullish momentum. By 2050, the forecast envisions an average of $96.60 with a min of $45.83 and a max of $199.39, delivering a 1,526.2% ROI and a bullish stance. These estimates are not guarantees; they reflect projections across a wide long-term horizon and are subject to uncertainty and market risk.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $12.44 with a low of $8.73 and a high of $19.21; the implied ROI is 109.4% and the sentiment is BULLISH. (Note: these are forecasted estimates, not guarantees.)
The forecast shows bullish sentiment from 2027 onward, with rising averages and positive ROI: 2027 avg $8.01 (ROI 34.8%), 2028 avg $9.23 (ROI 55.5%), 2029 avg $10.12 (ROI 70.4%), and 2030 avg $12.44 (ROI 109.4%). The longer-horizon outlook remains bullish with substantial upside potential in 2040 and 2050, but these are estimates, not guarantees.
The 2030 max price is $19.21, which is below $20; however, the 2031 max is $24.04, so it could exceed $20 in 2031 or later according to the forecast.
Current price is $5.94; market cap is $2.12B.
For 2050, the forecast shows an average price of $96.60 with a min of $45.83 and a max of $199.39, an ROI of 1,526.2%, and a bullish sentiment.
Precigen, Inc. Community Discussion
0Share your Precigen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.